The region-of-interest size impacts on Ki67 quantification by computer-assisted image analysis in breast cancer

被引:39
作者
Christgen, Matthias [1 ]
von Ahsen, Sabrina [1 ]
Christgen, Henriette [1 ]
Laenger, Florian [1 ]
Kreipe, Hans [1 ]
机构
[1] Hannover Med Sch, Inst Pathol, D-30625 Hannover, Germany
关键词
Breast cancer; Ki67; Immunohistochemistry; Slide scanning; Image analysis; LABELING INDEX; INTERNATIONAL KI67; PREDICTIVE-VALUE; EXPRESSION; PROLIFERATION; REPRODUCIBILITY; HETEROGENEITY; SIGNATURES; ACCURACY; ANTIBODY;
D O I
10.1016/j.humpath.2015.05.016
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Therapeutic decision-making in breast cancer depends on histopathologic biomarkers and is influenced by the Ki67 proliferation index. Computer-assisted image analysis (CAIA) promises to improve Ki67 quantification. Several commercial applications have been developed for semiautomated CAIA-based Ki67 quantification, many of which rely on measurements in user-defined regions of interest (ROIs). Because of intratumoral proliferative heterogeneity, definition of the ROI is an important step in the analytical procedure. This study explores the ROT size impacts on Ki67 quantification. Whole-slide sections of 100 breast cancers were immunostained with the anti Ki67 antibody 30-9 and were analyzed on the iScan Coreo digital pathology platform using a Food and Drug Administration cleared Ki67 quantification software version v5.3 (Virtuoso; Ventana, Tucson, TX). For each case, the Ki67 labeling index (LI) was determined in multiple ROIs of gradually increasing size centered around a high-proliferation area. The spatial Ki67 decline was modeled with nonlinear regression. Depending on the ROT size, the median Ki67 LI varied between 55% and 15%. The proportion of tumors classified as Ki67 low according to the St Gallen 2013/2015 cutoff increased from 2% to 56%, as the ROT size increased from 50 to 10 000 cells captured. The interrater reliability of conventional Ki67 assessment versus CAIA-based Ki67 quantification was also dependent on the ROT size and varied between slight and almost perfect agreement (Cohen kappa = 0.06-0.85). In conclusion, the ROT size is a critically important parameter for semiautomated Ki67 quantification by CAIA. Ki67 LIs determined on platforms like iScan Coreo/Virtuoso require an ROT size adjustment, for which we offer a downloadable data transformation tool. (C) 2015 Elsevier Inc. All rights reserved.
引用
收藏
页码:1341 / 1349
页数:9
相关论文
共 36 条
[1]   MIB1/Ki-67 labelling index can classify grade 2 breast cancer into two clinically distinct subgroups [J].
Aleskandarany, Mohammed A. ;
Rakha, Emad A. ;
Macmillan, R. Douglas ;
Powe, Desmond G. ;
Ellis, Ian O. ;
Green, Andrew R. .
BREAST CANCER RESEARCH AND TREATMENT, 2011, 127 (03) :591-599
[2]   Astronomical algorithms for automated analysis of tissue protein expression in breast cancer [J].
Ali, H. R. ;
Irwin, M. ;
Morris, L. ;
Dawson, S-J ;
Blows, F. M. ;
Provenzano, E. ;
Mahler-Araujo, B. ;
Pharoah, P. D. ;
Walton, N. A. ;
Brenton, J. D. ;
Caldas, C. .
BRITISH JOURNAL OF CANCER, 2013, 108 (03) :602-612
[3]   Systematic Analysis of Breast Cancer Morphology Uncovers Stromal Features Associated with Survival [J].
Beck, Andrew H. ;
Sangoi, Ankur R. ;
Leung, Samuel ;
Marinelli, Robert J. ;
Nielsen, Torsten O. ;
van de Vijver, Marc J. ;
West, Robert B. ;
van de Rijn, Matt ;
Koller, Daphne .
SCIENCE TRANSLATIONAL MEDICINE, 2011, 3 (108)
[4]   Oncogenic PIK3CA mutations in lobular breast cancer progression [J].
Christgen, Matthias ;
Noskowicz, Monika ;
Schipper, Elisa ;
Christgen, Henriette ;
Heil, Charlotte ;
Krech, Till ;
Laenger, Florian ;
Kreipe, Hans ;
Lehmann, Ulrich .
GENES CHROMOSOMES & CANCER, 2013, 52 (01) :69-80
[5]   Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial† [J].
Denkert, C. ;
Loibl, S. ;
Mueller, B. M. ;
Eidtmann, H. ;
Schmitt, W. D. ;
Eiermann, W. ;
Gerber, B. ;
Tesch, H. ;
Hilfrich, J. ;
Huober, J. ;
Fehm, T. ;
Barinoff, J. ;
Jackisch, C. ;
Prinzler, J. ;
Ruediger, T. ;
Erbstoesser, E. ;
Blohmer, J. U. ;
Budczies, J. ;
Mehta, K. M. ;
von Minckwitz, G. .
ANNALS OF ONCOLOGY, 2013, 24 (11) :2786-2793
[6]   Proliferation and apoptosis as markers of benefit in neoadjuvant endocrine therapy of breast cancer [J].
Dowsett, M ;
Smith, IE ;
Ebbs, SR ;
Dixon, JM ;
Skene, A ;
Griffith, C ;
Boeddinghaus, I ;
Salter, J ;
Detre, S ;
Hills, M ;
Ashley, S ;
Francis, S ;
Walsh, G ;
A'Hern, R .
CLINICAL CANCER RESEARCH, 2006, 12 (03) :1024S-1030S
[7]   Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer [J].
Dowsett, Mitch ;
Smith, Ian E. ;
Ebbs, Stephen R. ;
Dixon, J. Michael ;
Skene, Anthony ;
A'Hern, Roger ;
Salter, Janine ;
Detre, Simone ;
Hills, Margaret ;
Walsh, Geraldine .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2007, 99 (02) :167-170
[8]   Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group [J].
Dowsett, Mitch ;
Nielsen, Torsten O. ;
A'Hern, Roger ;
Bartlett, John ;
Coombes, R. Charles ;
Cuzick, Jack ;
Ellis, Matthew ;
Henry, N. Lynn ;
Hugh, Judith C. ;
Lively, Tracy ;
McShane, Lisa ;
Paik, Soon ;
Penault-Llorca, Frederique ;
Prudkin, Ljudmila ;
Regan, Meredith ;
Salter, Janine ;
Sotiriou, Christos ;
Smith, Ian E. ;
Viale, Giuseppe ;
Zujewski, Jo Anne ;
Hayes, Daniel F. .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2011, 103 (22) :1656-1664
[9]   Proliferative activity in human breast cancer: Ki-67 automated evaluation and the influence of different Ki-67 equivalent antibodies [J].
Fasanella, S. ;
Leonardi, E. ;
Cantaloni, C. ;
Eccher, C. ;
Bazzanella, I. ;
Aldovini, D. ;
Bragantini, E. ;
Morelli, L. ;
Cuorvo, L. V. ;
Ferro, A. ;
Gasperetti, F. ;
Berlanda, G. ;
Dalla Palma, P. ;
Barbareschi, M. .
DIAGNOSTIC PATHOLOGY, 2011, 6
[10]  
GERDES J, 1984, J IMMUNOL, V133, P1710